When an infection attacks the human body’s immune system, it reacts with inflammation as a natural protective measure. The inflammation helps reduce damage to the tissue. It also acts as a disinfectant to clean the affected area of any pathogens and germs. Inflammation happens as the immune cells, and fluid cells start the process of homeostasis in the infected area.

However, inflammation must lessen once the infection has cleared off, or else it can become toxic to the body. If the immune system is activated, conditions such as auto-immune disease or chronic inflammations can happen. This is where retrograde signals come in handy. They fire messages that inform the immune cells to withdraw from the recently healed area and reduce the inflammation.

Many products, including CBD, have recently come on the market and it’s important to understand the science of how those products affect the endocannabinoid system before selling/reselling products. After reviewing this post, you’ll be better equipped to how starting an online CBD business impacts the endocannabinoid system of your customers.

Endocannabinoid Deficiency: What Is It?

Endocannabinoid deficiency is a medical theory posited by Dr. Ethan Russo., the Director of Research and Development of the International Cannabis and Cannabinoids Institute (ICCI). It connects lower levels of endocannabinoids and improper functioning of the endocannabinoid system to several common ailments. 

Conditions and symptoms like irritable bowel syndrome, migraines, and fibromyalgia are all thought to be impacted or caused by an endocannabinoid deficiency. Most of the conditions linked to poor ECS functioning are usually thought of as chronic and incurable. Sufferers can expect to deal with symptoms for the rest of their lives. 

But now, Clinical Endocannabinoid Deficiency (CED) offers some home for those with chronic illnesses. Russo suggests that since most of these ailments are acquired rather than congenital, a disturbance to the ECS is to blame. If that’s true, then it opens up the possibility for relief or reversal down the road. 

Current Theories

Dr. Russo was the first to pose the theory of CED back in 2001. He’s continued study in the area since then, publishing several additional papers on the subject. 

His 2016 paper, “Clinical Endocannabinoid Deficiency Reconsidered,” he came back to the topic with a new perspective based on additional, substantive evidence found over the years. 

He outlined three new points:

  1. Migraine sufferers showed statistically significant depressed levels of anandamide.
  2. PTSD sufferers showed decreased levels of ECS functioning.
  3. Clinical data showed that lifestyle changes and cannabinoid treatment produced evidence of better sleep, improved pain levels, and other benefits.

While Russo’s study mainly focused on migraines, IBS, and fibromyalgia, there are additional illnesses that are also being classified underneath CED. These include, but are not limited to:

  • Glaucoma
  • PTSD
  • Colic
  • Repeated miscarriages
  • Phantom pain
  • Neuropathy
  • Cystic fibrosis
  • Bipolar disorder
  • Hyperemesis gravidarum

While there’s still much to be learned about the inner-workings of the ECS and how CED might influence common chronic illness, current research points toward hope for relief, treatment, or even reversal somewhere down the road. 

Future Research

The identification of the ECS is so new that many physicians actively practicing today have very little background in it. Further research is now necessary for us to understand the severity of ECS’s role in everyday biological functions. 

Over the past ten years or so, ECS has become the target focus of many scientific studies. Researchers have looked into its implications in different physiological conditions in both peripheral and central nervous systems.  

Further down the road, cannabinoid researchers hope to learn more about how modulating ECS activity affects a wide range of conditions. Some specific conditions to be studied include:

  • Hypertension
  • Obesity
  • Osteoporosis
  • Huntington’s disease
  • Parkinson’s
  • Anxiety and mood disorders
  • Multiple sclerosis
  • Stroke
  • Spinal Cord Injury

Some scientists also expect to study the use of plant-derived cannabinoids to modify and regulate the ECS and, thus, improve symptoms.

Some research shows this to be a useful tactic to reduce anxiety disorders.

What is endocannabinoid deficiency? In short, endocannabinoid deficiency is a medical theory that links decreased levels of endocannabinoids and improper functioning of the endocannabinoid system to many chronic disorders. 

Since the endocannabinoid system is found within almost every other biological system, it has the potential to impact and interfere with several physiological processes.